SHENZHEN Hemogen Therapeutic Co., Ltd.

Hemogen announced the publication of clinical results for its lead gene therapy candidate, hemo-cel (HGI-001 injection), in the peer-reviewed journal ...

Leveraging years of research and translational experience in hematopoietic stem cell gene therapy (HSC-GT), Hemogen was invited to author the rev...

Chiang Mai, Thailand — November 24, 2025Hemogen Therapeutics was invited to participate in the inaugural meeting of the Southeast Asia Thalassemia Pre...

On November 14, 2025, the Joint Regulatory Mechanism Office for the Cross-Border Management of Special Biomedical Items in Shenzhen announced the prop...

Shenzhen, China — November 2025Hemogen Therapeutic announced that it has been awarded the “Outstanding Clinical Achievement in Cell Therapy” at the 14...

In the field of cell and gene therapy (CGT), efficient and stable cell purification and elutriation are the core links to ensure efficacy and safety. ...

Shenzhen Hemogen Therapeutic Co., Ltd. (hereinafter referred to as “Hemogen”) has achieved a significant milestone in its international...

Thalassemia is a rare, inherited blood disorder caused by mutations in the genes involved in hemoglobin production that cause the body to produce less...